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Abstract
Background: Hepatitis C virus (HCV) infection is the leading cause of chronic hepatitis which progresses to
hepatocellular carcinoma (HCC) afflicting > 170 million people worldwide. HCV 3a is the most common genotype
(about 70% of all genotypes) circulating in Pakistan. Expression of HCV individual gene of 3a would facilitate
therapeutic and vaccines strategies against chronic HCV and liver Cirrhosis. The aim of the present study was the
establishment of stable Huh-7 cell lines expressing structural and non structural proteins of HCV Genotype 3a
Pakistani isolate obtained from chronic HCV patients.
Methods: Blood samples were obtained from chronic HCV-3a positive patients. HCV individual genes were
amplified using PCR with gene specific primers having restriction sites. These gene amplicons were cloned in
mammalian expression vector PcDNA3.1+. Huh-7 cell lines were transfected with these constructed plasmids
having structural or non-structural HCV genes in confluent cells with lipofectamine. Positive clones were selected
with G418 and then confirmed by genome PCR. Subsequently, transcription and expression of the integrated
genes were demonstrated by RT-PCR, sequencing and Western blot analysis.
Results: We successfully cloned and express five HCV-3a genes in PcDNA3.1+ mammalian expression vector.
Results of western blot and sequencing PCR confirmed the stable expression of these five genes.
Conclusion: The stable cell-lines expressing HCV-3a individual genes would be a useful tool to investigate the role
of various HCV proteins on HCV disease outcome and testing of new therapeutic strategies against HCV.
Background
Hepatitis C virus (HCV) is an enveloped plus-strand
RNA virus of family Flaviviridae [1,2]. HCV is a major
leading cause of chronic liver disease [3]. An estimated
170-200 million persons worldwide are infected with
HCV [4-6]. Studies on virus replication and pathogenesis
having difficulties due to the unavailability of consistent
and efficient cell culture systems, even though increasing
knowledge of genome structure and individual viral pro-
teins [7]. The HCV genome is approximately 9.6 kb in
length and consists of a single open reading frame (ORF)
encoding a polyprotein of about 3,000 amino acids and
un-translated regions (UTRs) located at the 5’and 3’ ter-
minus of the genome [8,9].
At the 5’ end HCV genome there are structural genes;
the nucleocapsid region core (C), and the envelope regions
(E1 and E2). The 5’ UTR and C are conserved regions,
while the envelope domain E2/NS1 encloses the hyper
variable region [10,11]. After the C gene towards the 3’
end, are six non-structural regions (NS2, NS3, NS4A,
NS4B, NS5a & NS5B) [7,12]. Viral proteins included in
various immunoassays and in the recombinant immuno-
blot assay are presented below their corresponding genes
[13]. HCV does not integrate into the host genome as it
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any medium, provided the original work is properly cited.does not replicate via a DNA intermediate. Even if the in-
vitro HCV replication remains a challenge, the chimpan-
zee is the only important experimental animal model [13].
At the 5’UTR, an internal ribosome entry site (IRES) is
located where in a cap-independent manner, viral proteins
are expressed. There are 10 viral proteins: core; envelope
protein 1 (E1) and E2 are structural proteins that consti-
tute the virion; a small protein that is essential for protein
assembly [10,11,14] and six non structural proteins (NS2,
NS3, NS4A/B and NS5A/B).
T h ec o r ep r o t e i no fH C Vf o r m st h en u c l e o c a p s i do f
the virus. It binds with RNA and also interacts with
numerous cellular proteins. Various host cell functions
such as gene transcription, lipid metabolism, apoptosis
and certain signaling pathways are also reported to have
interaction with core protein [15]. The associations of
core protein with the induction of steatosis and HCC
have also been reported [16]. HCV core Ag proved to
be useful for performing HCV RNA measurement
among dialysis patients in routine laboratories without
the need for special equipment or training [17].
E1 protein is associated with the membrane fraction
[18]. A direct role for the C-terminal domain in E1 mem-
brane association was identified in the soluble phase by
the truncated mutant E1t [19]. The HCV E1 protein hav-
ing good specificity and could be used in the diagnosis of
HCV infection [20] can become useful tools in anti-HCV
vaccine research [21]. The NS2 protein is a 23-kDa hydro-
phobic transmembrane, anchored to the endoplasmic reti-
culum (ER) [22,23] its function is reliant on the
microsomal membranes occurrence, but the function of
the NS2 protein in cells is still very poorly understood
[24,25]. It has been found that the HCV NS2 protein inhi-
bits cell proliferation and induces cell cycle arrest in the S-
phase in mammalian cells through down-regulation of
cyclin A expression [24]. Nonstructural protein 4A
(NS4A) is a multifunctional protein with 54 amino acid
residues. It acts as a cofactor of NS3 serine protease and
plays an essential role in the NS4A-dependent cleavage at
the NS3-NS4A and NS4B-NS5A junctions [26,27]. Both
NS4A and NS4B proteins were previously demonstrated
to suppress translation in culture cells [28,29]. HCV NS4B
is a highly hydrophobic, localized to the endoplasmic reti-
culum (ER) and induces a pattern of cytoplasmic foci posi-
tive for markers of the ER through four transmembrane
segments [30]. NS4B is also a helper factor for the HCV
RNA dependent RNA polymerase suggested by the muta-
genesis studies of the nucleotide binding motif of NS4B
[31]. The involvement of HCV NS4B in IFN-alpha resis-
tance was also reported by some groups [32,33]. However
no such study is available on the construction of these
expressions vectors from Pakistan where the rate of HCV
is 8-10% in general population and novel and chief drugs
are required to treat so huge number of cases.
Therefore, in this study, we have constructed five
expression vectors encoding structural (core and envel-
ope1) and nonstructural (NS2, NS4A, NS4B) genes from
local HCV isolates and checked their stable expression
in Huh-7 cell line. These expression vectors have the
potential to be use for testing of new developed drugs
in cell culture system.
Methods
Sample collection
Chronic HCV infected with Genotype 3a positive sam-
ples were obtained from Division of Molecular Virology
and Molecular Diagnostics, National Centre of Excel-
lence in Molecular Biology (CEMB), Lahore, Pakistan.
HCV genotyping was carried out on positive HCV PCR
samples using type specific HCV genotyping methods as
described previously [34,35].
Construction of plasmid (HCV genes in mammalian
expression vector PcDNA3.1+)
From the HCV positive serum with 3a genotype, RNA
was extracted using Gentra RNA isolation kit (Gentra
System Pennsylvania, USA) and individual gene is
reverse transcribed using M-MLV (Invitrogen Life tech-
nologies, CA). HCV reference sequence of NZL1 #
D17763 was used for primer designing on Primer 3 soft-
ware, restriction sites and kozak sequences were added
after restriction analysis on web cutter and neb-cutter
primers sequences given in table 1. Each gene is ampli-
fied individually and completely. Amplified genes with
restriction sites were then cloned in mammalian expres-
sion vector PcDNA3.1+ (Invitrogen Life technologies,
CA). Each gene constructed plasmid were confirmed
through PCR, restriction digestion and sequenced. Indi-
vidual gene sequence submitted to genbank accession
numbers given in table 2.
Cell culture and transfection
Huh-7 cell lines were used maintained in Dulbecco’s
modified eagle medium (DMEM) supplemented with
100 μg/ml penicillin; streptomycin and 10% fetal bovine
serum (Sigma Aldrich, USA) at 37°C with 5% CO2. cells
were seeded in 24-well (1 × 10
5/well) or 6- well (5 ×
10
5/well) plates and cultured until they became 70-80%
confluent. Constructed plasmids about 3-4 ug of struc-
tural (core and E1) and non-structural (NS2, NS4A,
NS4B) HCV genes were transfected in confluent cells
with lipofectamine (Invitrogen Life technologies, CA)
after 6-8 hrs. of transfection media (with lipofectamine
and plasmid) was changed.
Isolation of RNA
RNA was isolated using Gentra Kit and reverse tran-
scribed to cDNA with reverse primer and specific genes
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confirmation.
Proteins extraction and Immuno-blot (Western blotting)
Cells were lysed and protein was extracted after 72 hrs.
after transfection and for single stable clones after 3
weeks in PLB (150 mM6/29/2011 NaCl, 1M Tris-Cl pH
7.4, 5 mM EDTA, 1% Triton X-100) proteinase inhibitor
and 1 mM PMSF, kept on ice for 15 min. 80-100 μgo f
total protein were loaded in each well on 10-12.5% SDS-
PAGE gels and electrophoretically blotted onto a
Hybond-C extra nitrocellulose membrane semi-dry blot-
ting apparatus (Bio-Rad). The membrane was blocked
for 1 hour with a 5% milk solution in Phosphate Buf-
fered Saline-0.05% Tween (PBS-T), washed three times
with 50 ml of PBS-T. A mixture of primary antibodies
for structural genes like core (sc-57800), E1 (sc-65459)
and non structural gene like NS4A (sc-52415), NS4B
(sc-65457) was added, each at a concentration of 1:500-
1:800 in 5 ml of PBS-T. After incubating at room tem-
perature for 1 hour, the membrane was washed 3 times
with PBS-T. A secondary antibody, rabbit anti-mouse
IgG, conjugated to alkaline phosphatase (Sigma), was
added at a dilution of 1/1000 in PBS-T, incubated at
room temperature for one hour. The membrane was
washed for three times with PBS-T. Substrate tablet
(NBT/BCIP) was dissolved in 1XPBS and blot was incu-
bated for 15-30 min.
Generation of stable cell lines of structural and non
structural proteins
After 72 hrs of transfection, cells were given selection
with G418 initially with 400 ug/ml for selecting stable
clones than after 14 days were given 200 ug/ml. The
medium was changed after every 72 hours day. Colonies
of G418 resistant cells were selected and grown further
Table 1 indicating HCV Gene and polyprotein sequences submitted in Genbank and their Accession Numbers
No. HCV Gene and polyprotein Sequences Accession Numbers
1. Core Hepatitis C virus isolate PKIS-1 polyprotein gene, partial cds. FJ851546.2
Hepatitis C virus isolate PKIS-2 core polyprotein gene, partial cds. HQ323687
Hepatitis C virus isolate PK-1 complete genome. GU294484.1
2. Envelope 1 Hepatitis C virus genotype 3a isolate PKIS-2 e1 complete polyprotein gene. HQ433527
Hepatitis C virus isolate PK-1 complete genome GU294484.1
3. Non-Structural 2 HCV genotype 3a Non-Structural2 NS2 region of Pakistani isolate. FJ865505
Hepatitis C virus clone 3a nonstructural protein 2 Pakistani isolate PKIS-2 polyprotein. HQ822055
Hepatitis C virus isolate PK-1 complete genome GU294484.1
4. Non-structural 4a Hepatitis C virus isolate PKIS-1 non structural 4a polyprotein gene, partial cds. HQ822054
Hepatitis C virus isolate PK-1 complete genome. GU294484.1
5. Non-structural 4b Hepatitis C virus isolate PK1 non-structural protein NS4b gene, partial cds. GQ325251
Hepatitis C virus isolate PKIS-2 non-structural protein NS4b gene, partial cds. HQ323685
Hepatitis C virus genotype 3a PKIS-3 non-structural protein NS4b. HQ433528
Hepatitis C virus genotype 3a isolate PKIS-4 non-structural protein 4b. HQ616144
Hepatitis C virus isolate PK-1 complete genome GU294484.1
Table 2 List of primers of each individual gene of HCV genotype 3a, Restriction sites worked successfully, Nucleotide
position in full length sequence reference sequence of NZL1 was used and number of nucleotides in each amplified
region
No. Genes Primer seq. 5’-3’ Restriction site No. of Nucleotides (amplified region)
1. CORE-IS ATGAGCACACTTCCTAAACCTCA Hind III
2. CORE-IAS ACTGGCTGCTGGATGAATTAAGC EcoR1 573
3. E1-IS CTAGAGTGGCGGAATACGTCTG Hind III
4. E1-IAS GGCGACCCCTGAGAACATAACC EcoR1 576
5. NS2-IS CTTTGGTCCCTAGCATTGC Hind III
6. NS2-IAS CCTCACGGCCTAATCGTGC EcoR1 642
7. NS4A-IS AGCACCTGGGTGTTGCTC Hind III
8. NS4A-IAS GCACTCCTCCATCTCATCGT EcoR1 168
9. NS4B-IS TCACAAGCTGCCCCATATATCG Hind III
10. NS4B-IAS GCTACAAGGGCTTGGGTAGTC Xba1 783
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sequencing.
Results
Figure 1 (a & b) showing amplified structural (core and
envelope1) and nonstructural (NS2, NS4A, NS4B) genes
of the exact sizes. These bands were confirmed by sequen-
cing and only the sequence confirmed genes were further
used in next experiment leading to the development of
expression vectors. The genes were then cloned in mam-
malian expression vector pcDNA 3.1+. The successful
clones of these genes in PcDNA3.1+ vector were con-
firmed using restriction digestion analysis. The results of
restriction digestions are shown in figure 2. This vector
has a CMV promoter which represents an effective mean
to transduce eukaryotic cells for transient and stable
expression studies. The cloned genes were sequenced in
both direction and the consensus sequence was matched
to HCV genotype 3a sequence when blast was done with
other HCV sequences in GenBank data base.
The expression vector was then linearized and trans-
fected into Huh7 cells by lipofectamine. Twenty-four
hours post transfection, selection was applied to the
transfected cells by growing them in the presence of 1
mg of G418/ml. About 80% of cells did not develop resis-
tance to the selecting agent, but in the long run it was
possible to identify G418-resistant cell clones, which
were picked after four weeks of culture and grown as
individual cell lines. Once the clones had been isolated
and individually grown as cell lines, the concentration of
neomycin was decreased to 500 μg/ml. The individual
cell lines showed some variability in growth rate.
T oc h e c ke x p r e s s i o no fv a r i o u sH C Vi n d i v i d u a lp r o -
teins produced from corresponding replicon clones, we
performed Western blot analyses with protein extracts
of transfected Huh-7 cells. Figure 3 showing the western
blot results of structural and non structural proteins.
The Western blot analysis identified specific bands of
the expected electrophoretic mobility. B-Actin was used
as a positive control. Antibodies of NS2 are not available
so it was proceed the same way that was confirmed by
sequence analysis and RT-PCR confirmed it. The
expression of these individual genes were confirmed by
RT PCR and sequencing. All the sequences were sub-
mitted to Genbank data base. Table 1 indicating HCV
Gene, polyprotein sequences submitted to Genbank data
base and their assigned Accession Numbers. Table 2
shows the list of primers of each individual gene of
HCV genotype 3a, restriction sites worked successfully,
Nucleotide position in full length reference sequence of
NZL1 was used and number of nucleotides in each
amplified region.
Discussion
Despite vigorous host immune response, 20% of those
infected with chronic HCV will eventually lead to HCC
[36]. The socio-economic burden of HCV infection
globally is striking with an urgent necessity to have bet-
ter information of viral pathogenesis in order to develop
new anti-HCV strategies.
To test novel drugs for its inhibitory action, an effi-
cient culture system is required for the amplification of
virus. To date an efficient and reliable culture system is
not available to amplify HCV [2] and this limitation pre-
vents the elaboration of reliable infection assays. Several
models based on the self-replication of engineered mini-
genomes in cell cultures, has been established for HCV
r e p l i c a t i o ni no t h e rr e g i o n so ft h ew o r l d[ 7 , 3 7 ] .T h e
HCV stable cell lines may be very useful in the study of
HCV genomic replication in that part of the world
Figure 1 a) Showing the amplified genes of Core (573), Envelope 1(576), Non-structural 2 (NS2, 642 bp) and Non Structural 4a (NS4A,
168 bp), b) lanes 2-5 (left to right) showing the complete amplified region of 783 bp of Non Structural 4b gene. From the HCV positive
serum with 3a genotype, RNA was extracted and individual gene was reverse transcribed using M-MLV. HCV reference sequence of NZL1 # D17763 was
used for primer designing on Primer 3 software, restriction sites and kozak sequences were added after restriction analysis on web cutter and neb-
cutter primers sequences. Each entire gene was amplified individually. Amplified genes with restriction sites were then cloned in mammalian expression
vector PcDNA3.1+.
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is the predominant genotype circulating in Pakistan
[34,38], therefore, new approaches based on this local
HCV genotype 3a are needed on urgent basis to study
HCV assembly and infection to design HCV cell entry
inhibitors and further to study the humoral immune
response against HCV. Therefore, we have developed
cell-culture based systems stably expressing two struc-
tural and three non-structural HCV individual genes
described in the current study.
T ot h eb e s to fo u rk n o w l e d g en oc e l lc u l t u r eb a s e d
system has yet been developed to propagate the replica-
tion expression of HCV 3a genes of Pakistani chronic
isolates in cultured mammalian cells. Because the exist-
ing replicon was generated using genotype 1b HCV
RNA, the present replicon system may not be used to
detect responses that are genotype and subtype-depen-
dent. Therefore this study was initiated to establish
stable cell lines expressing proteins of Pakistani HCV
genotype 3a isolates. The establishment of HCV geno-
type 3a cell lines stably expressing structural and non
structural proteins is an instrumental in the further
study of HCV replication and viral-host interaction of
genotype 3a. Viral and cellular factors required for HCV
replication will be defined by cutting edge gene and
micro-array, proteomics, protein-protein interactions
methodologies. Further investigation on these stable cell
lines must have direct impact on HCV disease outcome
and new therapeutic strategies will be designed.
Conclusion
In summary, we were able to develop vectors stably
expressing HCV individual proteins such as core, envel-
ope1 (Structural), NS2, NS4A and NS4B (Non-structural).
The stable cell line expressing individual HCV gene would
be useful in identifying the role of most important genes
in HCC and fibrosis development and studying the
mechanisms of each gene in HCV replication. Obviously,
novel therapeutic strategies are required on urgent basis as
the health costs for HCV-infected people are predicted to
spiral dramatically in the next decade. Further investiga-
tion on these stable cell lines must have direct impact on
HCV disease outcome and new therapeutic strategies will
be designed. This system with genes from HCV-3a strain
can be used for comparison studies with other strain-
derived systems developed in other areas for the analysis
of the effects of anti-HCV drugs.
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